These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33557999)

  • 1. (Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time.
    Boothe K
    Health Econ Policy Law; 2021 Oct; 16(4):424-439. PubMed ID: 33557999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Getting to the Table": Changing Ideas about Public and Patient Involvement in Canadian Drug Assessment.
    Boothe K
    J Health Polit Policy Law; 2019 Aug; 44(4):631-663. PubMed ID: 31305914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making legitimacy: Drug user representation in United Nations drug policy settings.
    Madden A; Lancaster K; Ritter A; Treloar C
    Int J Drug Policy; 2021 Jan; 87():103014. PubMed ID: 33129132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The legitimacy principle within French risk public policy: A reflective contribution to policy analytics.
    Merad M; Trump BD
    Sci Total Environ; 2018 Dec; 645():1309-1322. PubMed ID: 30248855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which public and why deliberate?--A scoping review of public deliberation in public health and health policy research.
    Degeling C; Carter SM; Rychetnik L
    Soc Sci Med; 2015 Apr; 131():114-21. PubMed ID: 25770463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
    Denburg AE; Giacomini M; Ungar WJ; Abelson J
    Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Representation and legitimacy in health policy formulation at a national level: perspectives from a study of health technology eligibility procedures in the United Kingdom.
    Milewa T
    Health Policy; 2008 Mar; 85(3):356-62. PubMed ID: 17936401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What are the key ingredients for effective public involvement in health care improvement and policy decisions? A randomized trial process evaluation.
    Boivin A; Lehoux P; Burgers J; Grol R
    Milbank Q; 2014 Jun; 92(2):319-50. PubMed ID: 24890250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disentangling patient and public involvement in healthcare decisions: why the difference matters.
    Fredriksson M; Tritter JQ
    Sociol Health Illn; 2017 Jan; 39(1):95-111. PubMed ID: 27862007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The which-hunt: assembling health technologies for assessment and rationing.
    Giacomini MK
    J Health Polit Policy Law; 1999 Aug; 24(4):715-58. PubMed ID: 10503155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When "Good Evidence" Is Not Enough: A Case of Global Malaria Policy Development.
    D'Souza BJ; Parkhurst JO
    Glob Chall; 2018 Sep; 2(9):1700077. PubMed ID: 31565347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public attitudes and values in priority setting.
    Peacock SJ
    Isr J Health Policy Res; 2015; 4():29. PubMed ID: 26097679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Digital Health Innovation Policy: A Portal to Alternative Futures in the Making.
    Bayram M; Springer S; Garvey CK; Özdemir V
    OMICS; 2020 Aug; 24(8):460-469. PubMed ID: 32511054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences and attitudes towards evidence-informed policy-making among research and policy stakeholders in the Canadian agri-food public health sector.
    Young I; Gropp K; Pintar K; Waddell L; Marshall B; Thomas K; McEwen SA; Rajić A
    Zoonoses Public Health; 2014 Dec; 61(8):581-9. PubMed ID: 24528517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Public health policies in Chile: seeking to regain trust].
    Cuadrado C
    Medwave; 2016 Sep; 16(8):e6532. PubMed ID: 27602919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LEGITIMACY OF MEDICINES FUNDING IN THE ERA OF ACCELERATED ACCESS.
    Pace J; Pearson SA; Lipworth W
    Int J Technol Assess Health Care; 2017 Jan; 33(6):700-707. PubMed ID: 28893332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why is tobacco control progress in Indonesia stalled? - a qualitative analysis of interviews with tobacco control experts.
    Astuti PAS; Assunta M; Freeman B
    BMC Public Health; 2020 Apr; 20(1):527. PubMed ID: 32306928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.
    Mintzes B; Barer M; Lexchin J; Bassett KL
    Res Social Adm Pharm; 2005 Jun; 1(2):310-30. PubMed ID: 17138480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.